Vernon, John A.; Golec, Joseph H.; Dimasi, Joseph A. - In: Health Economics 19 (2010) 8, pp. 1002-1005
In a widely cited article, DiMasi, Hansen, and Grabowski (2003) estimate the average pre-tax cost of bringing a new molecular entity to market. Their base case estimate, excluding post‐marketing studies, was $802 million (in $US 2000). Strikingly, almost half of this cost (or $399 million) is...
